Loading...
BioNexus Gene Lab Corp.
BGLC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$4.90
$0.02(0.41%)
BioNexus Gene Lab Corp. (BGLC) Financial Performance & Income Statement Overview
Review BioNexus Gene Lab Corp.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-2.66%
↓ 2.66%
Operating Income Growth
39.32%
↑ 39.32%
Net Income Growth
39.20%
↑ 39.20%
Operating Cash Flow Growth
-71.66%
↓ 71.66%
Operating Margin
-22.81%
↓ 22.81%
Gross Margin
13.68%
↑ 13.68%
Net Profit Margin
-22.86%
↓ 22.86%
ROE
-24.19%
↓ 24.19%
ROIC
-26.68%
↓ 26.68%
BioNexus Gene Lab Corp. (BGLC) Income Statement & Financial Overview
Review BioNexus Gene Lab Corp.'s (BGLC) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.14M | $2.52M | $2.63M | $1.97M |
| Cost of Revenue | $1.79M | $2.21M | $2.30M | $1.69M |
| Gross Profit | $343493.00 | $309234.00 | $326536.00 | $288720.00 |
| Gross Profit Ratio | $0.16 | $0.12 | $0.12 | $0.15 |
| R&D Expenses | $12139.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | -$148819.00 | $469404.00 | $2.13M | $759657.00 |
| Operating Expenses | -$136680.00 | $725454.00 | $1.66M | $29552.00 |
| Total Costs & Expenses | $1.66M | $2.94M | $3.97M | $2.45M |
| Interest Income | $23568.00 | $147641.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $5812.00 | $6193.00 | $4480.00 |
| Depreciation & Amortization | $0.00 | $43025.00 | $49075.00 | $31457.00 |
| EBITDA | -$618418.00 | -$373199.00 | -$1.29M | $290625.00 |
| EBITDA Ratio | -$0.29 | -$0.15 | -$0.49 | $0.15 |
| Operating Income | -$618418.00 | -$416220.00 | -$1.34M | $259168.00 |
| Operating Income Ratio | -$0.29 | -$0.16 | -$0.51 | $0.13 |
| Other Income/Expenses (Net) | -$4909.00 | -$5812.00 | -$6193.00 | -$4480.00 |
| Income Before Tax | -$623327.00 | -$422032.00 | -$1.34M | $254688.00 |
| Income Before Tax Ratio | -$0.29 | -$0.17 | -$0.51 | $0.13 |
| Income Tax Expense | $0.00 | -$73713.00 | $1555.00 | $55584.00 |
| Net Income | -$623327.00 | -$348319.00 | -$1.35M | $199104.00 |
| Net Income Ratio | -$0.29 | -$0.14 | -$0.51 | $0.10 |
| EPS | -$0.04 | -$0.02 | -$0.07 | $0.01 |
| Diluted EPS | -$0.04 | -$0.02 | -$0.07 | $0.01 |
| Weighted Avg Shares Outstanding | $17.97M | $17.97M | $17.97M | $17.67M |
| Weighted Avg Shares Outstanding (Diluted) | $17.97M | $17.97M | $17.97M | $17.67M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan